{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T05:25:50Z","timestamp":1743398750238},"reference-count":112,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2018,7,23]],"date-time":"2018-07-23T00:00:00Z","timestamp":1532304000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1007\/s11940-018-0521-6","type":"journal-article","created":{"date-parts":[[2018,7,23]],"date-time":"2018-07-23T02:10:18Z","timestamp":1532311818000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Novel Therapeutic Options in Treatment of Idiopathic Inflammatory Myopathies"],"prefix":"10.1007","volume":"20","author":[{"given":"Namita A.","family":"Goyal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tahseen","family":"Mozaffar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,7,23]]},"reference":[{"issue":"1","key":"521_CR1","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/nan.12380","volume":"43","author":"Y Allenbach","year":"2017","unstructured":"\u2022\u2022 Allenbach Y, Benveniste O, Goebel HHH, Stenzel W. Review: integrated classification of inflammatory myopathies. Neuropathol Appl Neurobiol. 2017;43(1):62\u201381. A comprehensive review of new myositis-associated and myositis-specific autoantibodies and their influence on muscle pathology. This review integrates the clinical phenotype, serological findings and histopathological findings into a unified classification of myositis.","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"5","key":"521_CR2","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1002\/mus.24566","volume":"51","author":"AR Findlay","year":"2015","unstructured":"Findlay AR, Goyal NA, Mozaffar T. An overview of polymyositis and dermatomyositis. Muscle Nerve. 2015;51(5):638\u201356.","journal-title":"Muscle Nerve"},{"issue":"5","key":"521_CR3","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1097\/WCO.0000000000000376","volume":"29","author":"O Benveniste","year":"2016","unstructured":"Benveniste O, Stenzel W, Allenbach Y. Advances in serological diagnostics of inflammatory myopathies. Curr Opin Neurol. 2016;29(5):662\u201373.","journal-title":"Curr Opin Neurol"},{"issue":"1","key":"521_CR4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s40478-016-0308-5","volume":"4","author":"C Preu\u00dfe","year":"2016","unstructured":"Preu\u00dfe C, Allenbach Y, Hoffmann O, Goebel H-HH, Pehl D, Radke J, et al. Differential roles of hypoxia and innate immunity in juvenile and adult dermatomyositis. Acta Neuropathol Commun. 2016;4(1):45.","journal-title":"Acta Neuropathol Commun"},{"issue":"6","key":"521_CR5","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1093\/brain\/awy105","volume":"141","author":"L Ladislau","year":"2018","unstructured":"\u2022 Ladislau L, Su\u00e1rez-Calvet X, Toquet S, Landon-Cardinal O, Amelin D, Depp M, et al. JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis. Brain. 2018;141(6):1609\u201321. An important recent paper that highlights the role of interferon and JAK\/STAT pathway in DM.","journal-title":"Brain"},{"issue":"6","key":"521_CR6","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.nmd.2015.02.014","volume":"25","author":"J Vlekkert","year":"2015","unstructured":"Vlekkert J, Hoogendijk JE, Visser M. Myositis with endomysial cell invasion indicates inclusion body myositis even if other criteria are not fulfilled. Neuromuscul Disord. 2015;25(6):451\u20136.","journal-title":"Neuromuscul Disord"},{"issue":"2","key":"521_CR7","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/ana.410160206","volume":"16","author":"K Arahata","year":"1984","unstructured":"Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. I: quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol. 1984;16(2):193\u2013208.","journal-title":"Ann Neurol"},{"issue":"2","key":"521_CR8","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/ana.410190203","volume":"19","author":"K Arahata","year":"1986","unstructured":"Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. III: immunoelectron microscopy aspects of cell-mediated muscle fiber injury. Ann Neurol. 1986;19(2):112\u201325.","journal-title":"Ann Neurol"},{"issue":"2","key":"521_CR9","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1002\/ana.410230210","volume":"23","author":"K Arahata","year":"1988","unstructured":"\u2022\u2022 Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. IV: cell-mediated cytotoxicity and muscle fiber necrosis. Ann Neurol. 1988;23(2):168\u201373. A classical paper that established the importance of demonstrating muscle fiber invasion of non-necrotic fibers and subsequent necrosis as the hallmark of PM and IBM. All of the papers in this series (references 7-12 are a must read for students of myositis).","journal-title":"Ann Neurol"},{"issue":"5","key":"521_CR10","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/ana.410230511","volume":"23","author":"K Arahata","year":"1988","unstructured":"Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. V: identification and quantitation of T8+ cytotoxic and T8+ suppressor cells. Ann Neurol. 1988;23(5):493\u20139.","journal-title":"Ann Neurol"},{"issue":"3","key":"521_CR11","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/0046-8177(89)90128-7","volume":"20","author":"AM Emslie-Smith","year":"1989","unstructured":"Emslie-Smith AM, Arahata K, Engel AG. Major histocompatibility complex class I antigen expression, immunolocalization of interferon subtypes, and T cell-mediated cytotoxicity in myopathies. Hum Pathol. 1989;20(3):224\u201331.","journal-title":"Hum Pathol"},{"issue":"2","key":"521_CR12","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/ana.410160207","volume":"16","author":"AG Engel","year":"1984","unstructured":"Engel AG, Arahata K. Monoclonal antibody analysis of mononuclear cells in myopathies. II: phenotypes of autoinvasive cells in polymyositis and inclusion body myositis. Ann Neurol. 1984;16(2):209\u201315.","journal-title":"Ann Neurol"},{"key":"521_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-004552","volume":"4","author":"S Brady","year":"2014","unstructured":"Brady S, Squier W, Sewry C, Hanna M, Hilton-Jones D, Holton JL. A retrospective cohort study identifying the principal pathological features useful in the diagnosis of inclusion body myositis. BMJ Open. 2014;4:e004552.","journal-title":"BMJ Open"},{"issue":"3","key":"521_CR14","first-page":"240","volume":"25","author":"EJ Yunis","year":"1971","unstructured":"Yunis EJ, Samaha FJ. Inclusion body myositis. Lab Investig. 1971;25(3):240\u20138.","journal-title":"Lab Investig"},{"issue":"1","key":"521_CR15","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1212\/WNL.28.1.8","volume":"28","author":"S Carpenter","year":"1978","unstructured":"Carpenter S, Karpati G, Heller I, Eisen A. Inclusion body myositis: a distinct variety of idiopathic inflammatory myopathy. Neurology. 1978;28(1):8\u201317.","journal-title":"Neurology"},{"issue":"3","key":"521_CR16","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.ncl.2014.04.001","volume":"32","author":"MM Dimachkie","year":"2014","unstructured":"Dimachkie MM, Barohn RJ. Inclusion body myositis. Neurol Clin. 2014;32(3):629\u201346.","journal-title":"Neurol Clin"},{"issue":"1","key":"521_CR17","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3233\/JND-150138","volume":"3","author":"MA Price","year":"2016","unstructured":"Price MA, Barghout V, Benveniste O, Christopher-Stine L, Corbett A, de Visser M, et al. Mortality and causes of death in patients with sporadic inclusion body myositis: survey study based on the clinical experience of specialists in Australia, Europe and the USA. J Neuromuscul Dis. 2016;3(1):67\u201375.","journal-title":"J Neuromuscul Dis"},{"issue":"1","key":"521_CR18","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/nan.12384","volume":"43","author":"CC Weihl","year":"2017","unstructured":"Weihl CC, Mammen AL. Sporadic inclusion body myositis\u2014a myodegenerative disease or an inflammatory myopathy. Neuropathol Appl Neurobiol. 2017;43(1):82\u201391.","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"7","key":"521_CR19","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1056\/NEJMra1515161","volume":"374","author":"AL Mammen","year":"2016","unstructured":"\u2022\u2022 Mammen AL. Statin-associated autoimmune myopathy. N Engl J Med. 2016;374(7):664\u20139. An excellent review of HMGCR-antibody associated autoimmune necrotizing myopathy.","journal-title":"N Engl J Med"},{"key":"521_CR20","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/B978-0-444-63432-0.00025-6","volume":"133","author":"A Mammen","year":"2016","unstructured":"Mammen A. Autoimmune muscle disease. Handb Clin Neurol. 2016;133:467\u201384.","journal-title":"Handb Clin Neurol"},{"issue":"5","key":"521_CR21","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nrrheum.2018.56","volume":"14","author":"NJ McHugh","year":"2018","unstructured":"McHugh NJ, Tansley SL. Autoantibodies in myositis. Nat Rev Rheumatol. 2018;14(5):290\u2013302.","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"521_CR22","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s11940-011-0119-8","volume":"13","author":"MC Dalakas","year":"2011","unstructured":"Dalakas MC. Immunotherapy of inflammatory myopathies: practical approach and future prospects. Curr Treat Opin Neurol. 2011;13(3):311\u201323.","journal-title":"Curr Treat Opin Neurol"},{"issue":"3","key":"521_CR23","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.autrev.2011.05.013","volume":"11","author":"MC Dalakas","year":"2012","unstructured":"Dalakas MC. Pathogenesis and therapies of immune-mediated myopathies. Autoimmu Rev. 2012;11(3):203\u20136.","journal-title":"Autoimmu Rev"},{"issue":"5","key":"521_CR24","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/nrrheum.2018.42","volume":"14","author":"CV Oddis","year":"2018","unstructured":"Oddis CV, Aggarwal R. Treatment in myositis. Nat Rev Rheumatol. 2018;14(5):279\u201389.","journal-title":"Nat Rev Rheumatol"},{"issue":"27","key":"521_CR25","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","volume":"329","author":"MC Dalakas","year":"1993","unstructured":"Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med. 1993;329(27):1993\u20132000.","journal-title":"N Engl J Med"},{"issue":"3","key":"521_CR26","doi-asserted-by":"publisher","first-page":"382","DOI":"10.3109\/s10165-011-0534-4","volume":"22","author":"N Miyasaka","year":"2012","unstructured":"Miyasaka N, Hara M, Koike T, Saito E, Yamada M, Tanaka Y, et al. Effects of intravenous immunoglobulin therapy in Japanese patients with polymyositis and dermatomyositis resistant to corticosteroids: a randomized double-blind placebo-controlled trial. Mod Rheumatol. 2012;22(3):382\u201393.","journal-title":"Mod Rheumatol"},{"issue":"2","key":"521_CR27","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1002\/art.10053","volume":"46","author":"P Cherin","year":"2002","unstructured":"Cherin P, Pelletier S, Teixeira A, Laforet P, Genereau T, Simon A, et al. Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. Arthritis Rheum. 2002;46(2):467\u201374.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"521_CR28","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.autrev.2009.04.003","volume":"9","author":"MG Danieli","year":"2009","unstructured":"Danieli MG, Calcabrini L, Calabrese V, Marchetti A, Logullo F, Gabrielli A. Intravenous immunoglobulin as add on treatment with mycophenolate mofetil in severe myositis. Autoimm Rev. 2009;9(2):124\u20137.","journal-title":"Autoimm Rev"},{"issue":"1","key":"521_CR29","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1136\/jnnp.65.1.107","volume":"65","author":"FL Mastaglia","year":"1998","unstructured":"Mastaglia FL, Phillips BA, Zilko PJ. Immunoglobulin therapy in inflammatory myopathies. J Neurol Neurosurg Psychiatry. 1998;65(1):107\u201310.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"521_CR30","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3109\/s10165-007-0013-0","volume":"18","author":"E Saito","year":"2008","unstructured":"Saito E, Koike T, Hashimoto H, Miyasaka N, Ikeda Y, Hara M, et al. Efficacy of high-dose intravenous immunoglobulin therapy in Japanese patients with steroid-resistant polymyositis and dermatomyositis. Mod Rheumatol. 2008;18(1):34\u201344.","journal-title":"Mod Rheumatol"},{"issue":"6","key":"521_CR31","first-page":"1092","volume":"21","author":"P Cherin","year":"1994","unstructured":"Cherin P, Piette JC, Wechsler B, Bletry O, Ziza JM, Laraki R, et al. Intravenous gamma globulin as first line therapy in polymyositis and dermatomyositis: an open study in 11 adult patients. J Rheumatol. 1994;21(6):1092\u20137.","journal-title":"J Rheumatol"},{"key":"521_CR32","first-page":"588","volume":"27","author":"J Tian","year":"2008","unstructured":"Tian J, Gao JS, Chen JW, Li F, Xie X, Du JF. Efficacy and safety of the combined treatment with intravenous immunoglobulin and oral glucocorticoid in the elderly with dermatomyositis. Chin J Geriatr. 2008;27:588\u201390.","journal-title":"Chin J Geriatr"},{"issue":"1","key":"521_CR33","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/art.20913","volume":"53","author":"M Mosca","year":"2005","unstructured":"Mosca M, Strigini F, Carmignani A, D\u2019Ascanio A, Genazzani AR, Bombardieri S. Pregnant patient with dermatomyositis successfully treated with intravenous immunoglobulin therapy. Arthritis Rheum. 2005;53(1):119\u201321.","journal-title":"Arthritis Rheum"},{"issue":"12","key":"521_CR34","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1136\/ard.2011.153718","volume":"70","author":"CG Lam","year":"2011","unstructured":"Lam CG, Manlhiot C, Pullenayegum EM, Feldman BM. Efficacy of intravenous Ig therapy in juvenile dermatomyositis. Ann Rheum Dis. 2011;70(12):2089\u201394.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"521_CR35","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1002\/acr.20325","volume":"62","author":"I Marie","year":"2010","unstructured":"Marie I, Menard JFF, Hatron PY, Hachulla E, Mouthon L, Tiev K, et al. Intravenous immunoglobulins for steroid-refractory esophageal involvement related to polymyositis and dermatomyositis: a series of 73 patients. Arthritis Care Res. 2010;62(12):1748\u201355.","journal-title":"Arthritis Care Res"},{"issue":"9","key":"521_CR36","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1111\/jdv.12223","volume":"28","author":"T Bounfour","year":"2014","unstructured":"Bounfour T, Bouaziz JDD, B\u00e9zier M, Cordoliani F, Saussine A, Petit A, et al. Clinical efficacy of intravenous immunoglobulins for the treatment of dermatomyositis skin lesions without muscle disease. J Eur Acad Dermatol Venereol. 2014;28(9):1150\u20137.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"521_CR37","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.jaad.2013.06.007","volume":"69","author":"AN Femia","year":"2013","unstructured":"Femia AN, Eastham AB, Lam C, Merola JF, Qureshi AA, Vleugels RA. Intravenous immunoglobulin for refractory cutaneous dermatomyositis: a retrospective analysis from an academic medical center. J Am Acad Dermatol. 2013;69(4):654\u20137.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"521_CR38","doi-asserted-by":"publisher","first-page":"R149","DOI":"10.1186\/ar4332","volume":"15","author":"I Marie","year":"2013","unstructured":"Marie I, Hatron P-YY, Cherin P, Hachulla E, Diot E, Vittecoq O, et al. Functional outcome and prognostic factors in anti-Jo1 patients with antisynthetase syndrome. Arthritis Res Ther. 2013;15(5):R149.","journal-title":"Arthritis Res Ther"},{"issue":"25","key":"521_CR39","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1056\/NEJMoa032534","volume":"350","author":"JC Edwards","year":"2004","unstructured":"Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350(25):2572\u201381.","journal-title":"N Engl J Med"},{"issue":"3","key":"521_CR40","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa0909905","volume":"363","author":"JH Stone","year":"2010","unstructured":"Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221\u201332.","journal-title":"N Engl J Med"},{"issue":"7","key":"521_CR41","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.3899\/jrheum.101321","volume":"38","author":"B Bader-Meunier","year":"2011","unstructured":"Bader-Meunier B, Decaluwe H, Barnerias C, Gherardi R, Quartier P, Faye A, et al. Safety and efficacy of rituximab in severe juvenile dermatomyositis: results from 9 patients from the French Autoimmunity and Rituximab registry. J Rheumatol. 2011;38(7):1436\u201340.","journal-title":"J Rheumatol"},{"key":"521_CR42","doi-asserted-by":"publisher","first-page":"133","DOI":"10.2147\/DDDT.S33110","volume":"6","author":"T Levine","year":"2012","unstructured":"Levine T. Treating refractory dermatomyositis or polymyositis with adrenocorticotropic hormone gel: a retrospective case series. Drug Des Devel Ther. 2012;6:133\u20139.","journal-title":"Drug Des Devel Ther"},{"issue":"12","key":"521_CR43","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1093\/rheumatology\/ker088","volume":"50","author":"EA Mahler","year":"2011","unstructured":"Mahler EA, Blom M, Voermans NC, van Engelen BG, van Riel PL, Vonk MC. Rituximab treatment in patients with refractory inflammatory myopathies. Rheumatology. 2011;50(12):2206\u201313.","journal-title":"Rheumatology"},{"issue":"6","key":"521_CR44","first-page":"1009","volume":"27","author":"R Rios Fern\u00e1ndez","year":"2009","unstructured":"Rios Fern\u00e1ndez R, Callejas Rubio JLL, S\u00e1nchez Cano D, S\u00e1ez Moreno JAA, Ortego Centeno N. Rituximab in the treatment of dermatomyositis and other inflammatory myopathies. A report of 4 cases and review of the literature. Clin Exp Rheumatol. 2009;27(6):1009\u201316.","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"521_CR45","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/art.37754","volume":"65","author":"CV Oddis","year":"2013","unstructured":"Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum. 2013;65(2):314\u201324.","journal-title":"Arthritis Rheum"},{"key":"521_CR46","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1186\/s12891-015-0710-3","volume":"16","author":"AM Reed","year":"2015","unstructured":"\u2022 Reed AM, Crowson CS, Hein M, de Padilla CL, Olazagasti JM, Aggarwal R, et al. Biologic predictors of clinical improvement in rituximab-treated refractory myositis. BMC Musculoskelet Disord. 2015;16:257. This study showed the beneficial effect of B-cell depletion therapy on antibody-associated myositis.","journal-title":"BMC Musculoskelet Disord"},{"issue":"8","key":"521_CR47","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1093\/rheumatology\/kev004","volume":"54","author":"H Andersson","year":"2015","unstructured":"Andersson H, Sem M, Lund MB, Aal\u00f8kken TM, G\u00fcnther A, Walle-Hansen R, et al. Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease. Rheumatology. 2015;54(8):1420\u20138.","journal-title":"Rheumatology"},{"issue":"4","key":"521_CR48","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.rmed.2012.01.001","volume":"106","author":"I Marie","year":"2012","unstructured":"Marie I, Dominique S, Janvresse A, Levesque H, Menard JFF. Rituximab therapy for refractory interstitial lung disease related to antisynthetase syndrome. Respir Med. 2012;106(4):581\u20137.","journal-title":"Respir Med"},{"issue":"11","key":"521_CR49","doi-asserted-by":"publisher","first-page":"e0133702","DOI":"10.1371\/journal.pone.0133702","volume":"10","author":"Y Allenbach","year":"2015","unstructured":"Allenbach Y, Guiguet M, Rigolet A, Marie I, Hachulla E, Drouot L, et al. Efficacy of rituximab in refractory inflammatory myopathies associated with anti-synthetase auto-antibodies: an open-label, phase II trial. PLoS One. 2015;10(11):e0133702.","journal-title":"PLoS One"},{"issue":"3","key":"521_CR50","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s10067-014-2507-4","volume":"34","author":"AM Kerola","year":"2015","unstructured":"Kerola AM, Kauppi MJ. Abatacept as a successful therapy for myositis\u2014a case-based review. Clin Rheumatol. 2015;34(3):609\u201312.","journal-title":"Clin Rheumatol"},{"issue":"4","key":"521_CR51","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.jbspin.2011.03.022","volume":"78","author":"JL Musuruana","year":"2011","unstructured":"Musuruana JL, Cavallasca JA. Abatacept for treatment of refractory polymyositis. Joint Bone Spine. 2011;78(4):431\u20132.","journal-title":"Joint Bone Spine"},{"issue":"3","key":"521_CR52","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.jpeds.2011.11.057","volume":"160","author":"B Arabshahi","year":"2012","unstructured":"Arabshahi B, Silverman RA, Jones OY, Rider LG. Abatacept and sodium thiosulfate for treatment of recalcitrant juvenile dermatomyositis complicated by ulceration and calcinosis. J Pediatr. 2012;160(3):520\u20132.","journal-title":"J Pediatr"},{"issue":"1","key":"521_CR53","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1136\/annrheumdis-2017-211751","volume":"77","author":"A Tj\u00e4rnlund","year":"2018","unstructured":"Tj\u00e4rnlund A, Tang Q, Wick C, Dastmalchi M, Mann H, Tomasov\u00e1 Stud\u00fdnkov\u00e1 J, et al. Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial. Ann Rheum Dis. 2018;77(1):55\u201362.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"521_CR54","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1007\/s100670070027","volume":"19","author":"T Shimizu","year":"2000","unstructured":"Shimizu T, Tomita Y, Son K, Nishinarita S, Sawada S, Horie T. Elevation of serum soluble tumour necrosis factor receptors in patients with polymyositis and dermatomyositis. Clin Rheumatol. 2000;19(5):352\u20139.","journal-title":"Clin Rheumatol"},{"issue":"7","key":"521_CR55","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1007\/s10067-006-0325-z","volume":"26","author":"S Dold","year":"2007","unstructured":"Dold S, Justiniano ME, Marquez J, Espinoza LR. Treatment of early and refractory dermatomyositis with infliximab: a report of two cases. Clin Rheumatol. 2007;26(7):1186\u20138.","journal-title":"Clin Rheumatol"},{"issue":"9","key":"521_CR56","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1136\/ard.2005.048744","volume":"65","author":"P Efthimiou","year":"2006","unstructured":"Efthimiou P, Schwartzman S, Kagen LJ. Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients. Ann Rheum Dis. 2006;65(9):1233\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"521_CR57","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1159\/000070852","volume":"50","author":"GJ Hengstman","year":"2003","unstructured":"Hengstman GJ, van den Hoogen FH, Barrera P, Netea MG, Pieterse A, van de Putte LB, et al. Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-alpha: preliminary observations. Eur Neurol. 2003;50(1):10\u20135.","journal-title":"Eur Neurol"},{"issue":"4","key":"521_CR58","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1093\/rheumatology\/keh062","volume":"43","author":"H Sprott","year":"2004","unstructured":"Sprott H, Glatzel M, Michel BA. Treatment of myositis with etanercept (Enbrel), a recombinant human soluble fusion protein of TNF-alpha type II receptor and IgG1. Rheumatology. 2004;43(4):524\u20136.","journal-title":"Rheumatology"},{"issue":"9","key":"521_CR59","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1093\/rheumatology\/keh268","volume":"43","author":"I Uthman","year":"2004","unstructured":"Uthman I, El-Sayad J. Refractory polymyositis responding to infliximab. Rheumatology. 2004;43(9):1198\u20139.","journal-title":"Rheumatology"},{"issue":"1","key":"521_CR60","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1159\/000079547","volume":"52","author":"GJ Hengstman","year":"2004","unstructured":"Hengstman GJ, van den Hoogen FH, van Engelen BG. Treatment of dermatomyositis and polymyositis with anti-tumor necrosis factor-alpha: long-term follow-up. Eur Neurol. 2004;52(1):61\u20133.","journal-title":"Eur Neurol"},{"issue":"4","key":"521_CR61","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1093\/rheumatology\/keh079","volume":"43","author":"I Labioche","year":"2004","unstructured":"Labioche I, Liozon E, Weschler B, Loustaud-Ratti V, Soria P, Vidal E. Refractory polymyositis responding to infliximab: extended follow-up. Rheumatology. 2004;43(4):531\u20132.","journal-title":"Rheumatology"},{"issue":"5","key":"521_CR62","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s10067-009-1370-1","volume":"29","author":"Y Ishikawa","year":"2010","unstructured":"Ishikawa Y, Yukawa N, Ohmura K, Hosono Y, Imura Y, Kawabata D, et al. Etanercept-induced anti-Jo-1-antibody-positive polymyositis in a patient with rheumatoid arthritis: a case report and review of the literature. Clin Rheumatol. 2010;29(5):563\u20136.","journal-title":"Clin Rheumatol"},{"issue":"12","key":"521_CR63","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1093\/rheumatology\/keg388","volume":"42","author":"J Musia\u0142","year":"2003","unstructured":"Musia\u0142 J, Undas A, Celi\u0144ska-Lowenhoff M. Polymyositis associated with infliximab treatment for rheumatoid arthritis. Rheumatology. 2003;42(12):1566\u20138.","journal-title":"Rheumatology"},{"issue":"6","key":"521_CR64","doi-asserted-by":"publisher","first-page":"410","DOI":"10.3109\/s10165-006-0523-1","volume":"16","author":"Y Urata","year":"2006","unstructured":"Urata Y, Wakai Y, Kowatari K, Nitobe T, Mizushima Y. Polymyositis associated with infliximab treatment for rheumatoid arthritis. Mod Rheumatol. 2006;16(6):410\u20131.","journal-title":"Mod Rheumatol"},{"issue":"3","key":"521_CR65","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/ar1724","volume":"7","author":"M Flendrie","year":"2005","unstructured":"Flendrie M, Vissers WH, Creemers MC, de Jong EM, van de Kerkhof PC, van Riel PL. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther. 2005;7(3):76.","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"521_CR66","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1002\/art.22358","volume":"55","author":"HA Hall","year":"2006","unstructured":"Hall HA, Zimmermann B. Evolution of dermatomyositis during therapy with a tumor necrosis factor alpha inhibitor. Arthritis Rheum. 2006;55(6):982\u20134.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"521_CR67","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1001\/archdermatol.2010.142","volume":"146","author":"R Klein","year":"2010","unstructured":"Klein R, Rosenbach M, Kim EJ, Kim B, Werth VP, Dunham J. Tumor necrosis factor inhibitor-associated dermatomyositis. Arch Dermatol. 2010;146(7):780\u20134.","journal-title":"Arch Dermatol"},{"issue":"3\u20134","key":"521_CR68","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1159\/000114036","volume":"59","author":"GJ Hengstman","year":"2008","unstructured":"Hengstman GJ, De Bleecker JL, Feist E, Vissing J, Denton CP, Manoussakis MN, et al. Open-label trial of anti-TNF-alpha in dermato- and polymyositis treated concomitantly with methotrexate. Eur Neurol. 2008;59(3\u20134):159\u201363.","journal-title":"Eur Neurol"},{"issue":"12","key":"521_CR69","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1136\/ard.2007.077974","volume":"67","author":"M Dastmalchi","year":"2008","unstructured":"Dastmalchi M, Grundtman C, Alexanderson H, Mavragani CP, Einarsdottir H, Helmers SB, et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis. 2008;67(12):1670\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"521_CR70","first-page":"1802","volume":"33","author":"F Iannone","year":"2006","unstructured":"Iannone F, Scioscia C, Falappone PC, Covelli M, Lapadula G. Use of etanercept in the treatment of dermatomyositis: a case series. J Rheumatol. 2006;33(9):1802\u20134.","journal-title":"J Rheumatol"},{"issue":"3","key":"521_CR71","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/ana.22477","volume":"70","author":"Muscle Study Group","year":"2011","unstructured":"Muscle Study Group. A randomized, pilot trial of etanercept in dermatomyositis. Ann Neurol. 2011;70(3):427\u201336.","journal-title":"Ann Neurol"},{"issue":"1","key":"521_CR72","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1046\/j.1365-2990.1998.00092.x","volume":"24","author":"H Lepidi","year":"1998","unstructured":"Lepidi H, Frances V, Figarella-Branger D, Bartoli C, Machado-Baeta A, Pellissier JF. Local expression of cytokines in idiopathic inflammatory myopathies. Neruopathol Appl Neurobiol. 1998;24(1):73\u20139.","journal-title":"Neruopathol Appl Neurobiol"},{"issue":"5","key":"521_CR73","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1002\/art.1780400514","volume":"40","author":"I Lundberg","year":"1997","unstructured":"Lundberg I, Ulfgren AK, Nyberg P, Andersson U, Klareskog L. Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. Arthritis Rheum. 1997;40(5):865\u201374.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"521_CR74","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1002\/art.24689","volume":"60","author":"N Okiyama","year":"2009","unstructured":"Okiyama N, Sugihara T, Iwakura Y, Yokozeki H, Miyasaka N, Kohsaka H. Therapeutic effects of interleukin-6 blockade in a murine model of polymyositis that does not require interleukin-17A. Arthritis Rheum. 2009;60(8):2505\u201312.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"521_CR75","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1093\/rheumatology\/ker152","volume":"50","author":"M Narazaki","year":"2011","unstructured":"Narazaki M, Hagihara K, Shima Y, Ogata A, Kishimoto T, Tanaka T. Therapeutic effect of tocilizumab on two patients with polymyositis. Rheumatology. 2011;50(7):1344\u20136.","journal-title":"Rheumatology"},{"issue":"10","key":"521_CR76","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1093\/rheumatology\/keu234","volume":"53","author":"M Kondo","year":"2014","unstructured":"Kondo M, Murakawa Y, Matsumura T, Matsumoto O, Taira M, Moriyama M, et al. A case of overlap syndrome successfully treated with tocilizumab: a hopeful treatment strategy for refractory dermatomyositis? Rheumatology. 2014;53(10):1907\u20138.","journal-title":"Rheumatology"},{"issue":"1\u20132","key":"521_CR77","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2119\/2006-00085.Baechler","volume":"13","author":"EC Baechler","year":"2007","unstructured":"Baechler EC, Bauer JW, Slattery CA, Ortmann WA, Espe KJ, Novitzke J, et al. An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity. Mol Med. 2007;13(1\u20132):59\u201368.","journal-title":"Mol Med"},{"issue":"11","key":"521_CR78","doi-asserted-by":"publisher","first-page":"3784","DOI":"10.1002\/art.22928","volume":"56","author":"RJ Walsh","year":"2007","unstructured":"Walsh RJ, Kong SW, Yao Y, Jallal B, Kiener PA, Pinkus JL, et al. Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. Arthritis Rheum. 2007;56(11):3784\u201392.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"521_CR79","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1136\/annrheumdis-2012-202794","volume":"73","author":"BW Higgs","year":"2014","unstructured":"Higgs BW, Zhu W, Morehouse C, White WI, Brohawn P, Guo X, et al. A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-\u03b1 monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients. Ann Rheum Dis. 2014;73(1):256\u201362.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"521_CR80","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1136\/annrheumdis-2014-205278","volume":"73","author":"J Zou","year":"2014","unstructured":"Zou J, Li T, Huang X, Chen S, Guo Q, Bao C. Basiliximab may improve the survival rate of rapidly progressive interstitial pneumonia in patients with clinically amyopathic dermatomyositis with anti-MDA5 antibody. Ann Rheum Dis. 2014;73(8):1591\u20133.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"521_CR81","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1136\/ard.2008.091405","volume":"68","author":"O Krystufkov\u00e1","year":"2009","unstructured":"Krystufkov\u00e1 O, Vallerskog T, Helmers SB, Mann H, Putov\u00e1 I, Bel\u00e1cek J, et al. Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies. Ann Rheum Dis. 2009;68(6):836\u201343.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"521_CR82","doi-asserted-by":"publisher","first-page":"294","DOI":"10.3899\/jrheum.120555","volume":"40","author":"CM L\u00f3pez De Padilla","year":"2013","unstructured":"L\u00f3pez De Padilla CM, McNallan KT, Crowson CS, Bilgic H, Bram RJ, Hein MS, et al. BAFF expression correlates with idiopathic inflammatory myopathy disease activity measures and autoantibodies. J Rheumatol. 2013;40(3):294\u2013302.","journal-title":"J Rheumatol"},{"key":"521_CR83","first-page":"292","volume":"4","author":"T Levine","year":"2016","unstructured":"Levine T, Malone J, Efthimidiou P, Tandan R, Dikranian A, Levine A, et al. HP Acthar gel in dermatomyositis and polymyositis treatment registry: an interim analysis. J Neurol Disord. 2016;4:292.","journal-title":"J Neurol Disord"},{"key":"521_CR84","first-page":"9068061","volume":"2016","author":"A Patel","year":"2016","unstructured":"Patel A, Seely G, Aggarwal R. Repository corticotropin injection for treatment of idiopathic inflammatory myopathies. Case Rep Rheumatol. 2016;2016:9068061.","journal-title":"Case Rep Rheumatol"},{"issue":"5","key":"521_CR85","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1136\/annrheumdis-2017-212047","volume":"77","author":"R Aggarwal","year":"2018","unstructured":"Aggarwal R, Marder G, Koontz DC, Nandkumar P, Qi Z, Oddis CV. Efficacy and safety of adrenocorticotropic hormone gel in refractory dermatomyositis and polymyositis. Ann Rheum Dis. 2018;77(5):720\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"supplement","key":"521_CR86","first-page":"S489","volume":"46","author":"K Takada","year":"2002","unstructured":"Takada K, Bookbinder S, Furie R, Oddis C, Mojcik C, Mombara M, et al. A pilot study of eculizumab in patients with dermatomyositis. Arthritis Rheum. 2002;46(supplement):S489.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"521_CR87","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1002\/art.1780330908","volume":"33","author":"IN Targoff","year":"1990","unstructured":"Targoff IN, Johnson AE, Miller FW. Antibody to signal recognition particle in polymyositis. Arthritis Rheum. 1990;33(9):1361\u201370.","journal-title":"Arthritis Rheum"},{"key":"521_CR88","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13023-015-0277-y","volume":"10","author":"S Suzuki","year":"2015","unstructured":"Suzuki S, Nishikawa A, Kuwana M, Nishimura H, Watanabe Y, Nakahara J, et al. Inflammatory myopathy with anti-signal recognition particle antibodies: case series of 100 patients. Orphanet J Rare Dis. 2015;10:61.","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"521_CR89","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1002\/acr.20219","volume":"62","author":"R Valiyil","year":"2010","unstructured":"Valiyil R, Casciola-Rosen L, Hong G, Mammen A, Christopher-Stine L. Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series. Arthritis Care Res. 2010;62(9):1328\u201334.","journal-title":"Arthritis Care Res"},{"issue":"2","key":"521_CR90","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1002\/acr.22920","volume":"69","author":"I Pinal-Fernandez","year":"2017","unstructured":"Pinal-Fernandez I, Parks C, Werner JL, Albayda J, Paik J, Danoff SK, et al. Longitudinal course of disease in a large cohort of myositis patients with autoantibodies recognizing the signal recognition particle. Arthritis Care Res. 2017;69(2):263\u201370.","journal-title":"Arthritis Care Res"},{"issue":"3","key":"521_CR91","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1002\/art.30156","volume":"63","author":"AL Mammen","year":"2011","unstructured":"\u2022 Mammen AL, Chung T, Christopher-Stine L, Rosen P, Rosen A, Doering KR, et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum. 2011;63(3):713\u201321. The seminal paper that described the meticulous and methodical work that led to the discovery of the HMGCR-antibodies in necrotizing autoimmune myopathies.","journal-title":"Arthritis Rheum"},{"issue":"17","key":"521_CR92","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1056\/NEJMc1506163","volume":"373","author":"AL Mammen","year":"2015","unstructured":"Mammen AL, Tiniakou E. Intravenous immune globulin for statin-triggered autoimmune myopathy. N Engl J Med. 2015;373(17):1680\u20132.","journal-title":"N Engl J Med"},{"issue":"3","key":"521_CR93","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1212\/WNL.48.3.712","volume":"48","author":"MC Dalakas","year":"1997","unstructured":"Dalakas MC, Sonies B, Dambrosia J, Sekul E, Cupler E, Sivakumar K. Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study. Neurology. 1997;48(3):712\u20136.","journal-title":"Neurology"},{"issue":"3","key":"521_CR94","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1212\/WNL.56.3.323","volume":"56","author":"MC Dalakas","year":"2001","unstructured":"Dalakas MC, Koffman B, Fujii M, Spector S, Sivakumar K, Cupler E. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology. 2001;56(3):323\u20137.","journal-title":"Neurology"},{"issue":"4","key":"521_CR95","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1212\/01.WNL.0000134675.98525.79","volume":"63","author":"Muscle Study Group","year":"2004","unstructured":"Muscle Study Group. Randomized pilot trial of high-dose betaINF-1a in patients with inclusion body myositis. Neurology. 2004;63(4):718\u201320.","journal-title":"Neurology"},{"issue":"2 Suppl 1","key":"521_CR96","first-page":"4","volume":"66","author":"RJ Barohn","year":"2006","unstructured":"Barohn RJ, Herbelin L, Kissel JT, King W, McVey AL, Saperstein DS, et al. Pilot trial of etanercept in the treatment of inclusion-body myositis. Neurology. 2006;66(2 Suppl 1):4.","journal-title":"Neurology"},{"key":"521_CR97","doi-asserted-by":"crossref","unstructured":"Lilleker JB, Bukhari M, Chinoy H. Rapamycin for inclusion body myositis: targeting non-inflammatory mechanisms. Rheumatology (Oxford, England). 2018.","DOI":"10.1093\/rheumatology\/key043"},{"issue":"1\u20132","key":"521_CR98","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jns.2013.08.007","volume":"334","author":"ML Kosmidis","year":"2013","unstructured":"Kosmidis ML, Alexopoulos H, Tzioufas AG, Dalakas MC. The effect of anakinra, an IL1 receptor antagonist, in patients with sporadic inclusion body myositis (sIBM): a small pilot study. J Neurol Sci. 2013;334(1\u20132):123\u20135.","journal-title":"J Neurol Sci"},{"issue":"Pt 6","key":"521_CR99","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1093\/brain\/awp104","volume":"132","author":"MC Dalakas","year":"2009","unstructured":"Dalakas MC, Rakocevic G, Schmidt J, Salajegheh M, McElroy B, Harris-Love MO, et al. Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain. 2009;132(Pt 6):1536\u201344.","journal-title":"Brain"},{"key":"521_CR100","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12883-016-0568-5","volume":"16","author":"K Schmidt","year":"2016","unstructured":"Schmidt K, Kleinschnitz K, Rakocevic G, Dalakas MC, Schmidt J. Molecular treatment effects of alemtuzumab in skeletal muscles of patients with IBM. BMC Neurol. 2016;16:48.","journal-title":"BMC Neurol"},{"issue":"24","key":"521_CR101","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1212\/WNL.0000000000001070","volume":"83","author":"AA Amato","year":"2014","unstructured":"\u2022 Amato AA, Sivakumar K, Goyal N, David WS, Salajegheh M, Praestgaard J, et al. Treatment of sporadic inclusion body myositis with bimagrumab. Neurology. 2014;83(24):2239\u201346. Phase II trial of an activin receptor IIB (ActRIIB) inhibitor in IBM, which led to the larger phase 3 pivotal negative study in IBM.","journal-title":"Neurology"},{"issue":"331","key":"521_CR102","doi-asserted-by":"publisher","first-page":"331ra41","DOI":"10.1126\/scitranslmed.aad4583","volume":"8","author":"M Ahmed","year":"2016","unstructured":"Ahmed M, Machado PM, Miller A, Spicer C, Herbelin L, He J, et al. Targeting protein homeostasis in sporadic inclusion body myositis. Sci Transl Med. 2016;8(331):331ra41.","journal-title":"Sci Transl Med"},{"issue":"Pt 11","key":"521_CR103","doi-asserted-by":"publisher","first-page":"3176","DOI":"10.1093\/brain\/awr213","volume":"134","author":"O Benveniste","year":"2011","unstructured":"Benveniste O, Guiguet M, Freebody J, Dubourg O, Squier W, Maisonobe T, et al. Long-term observational study of sporadic inclusion body myositis. Brain. 2011;134(Pt 11):3176\u201384.","journal-title":"Brain"},{"issue":"4","key":"521_CR104","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.ymthe.2017.02.015","volume":"25","author":"JR Mendell","year":"2017","unstructured":"\u2022\u2022 Mendell JR, Sahenk Z, Al-Zaidy S, Rodino-Klapac LR, Lowes LP, Alfano LN, et al. Follistatin gene therapy for sporadic inclusion body myositis improves functional outcomes. Mol Ther. 2017;25(4):870\u20139. Proof of concept study that myostatin antagonism can result in not only increase in muscle mass but also improvement in muscle strength and function.","journal-title":"Mol Ther"},{"issue":"5","key":"521_CR105","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1002\/art.22780","volume":"57","author":"H Alexanderson","year":"2007","unstructured":"Alexanderson H, Dastmalchi M, Esbj\u00f6rnsson-Liljedahl M, Opava CH, Lundberg IE. Benefits of intensive resistance training in patients with chronic polymyositis or dermatomyositis. Arthritis Rheum. 2007;57(5):768\u201377.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"521_CR106","doi-asserted-by":"publisher","first-page":"R83","DOI":"10.1186\/ar4263","volume":"15","author":"L Alemo Munters","year":"2013","unstructured":"Alemo Munters L, Dastmalchi M, Katz A, Esbj\u00f6rnsson M, Loell I, Hanna B, et al. Improved exercise performance and increased aerobic capacity after endurance training of patients with stable polymyositis and dermatomyositis. Arthritis Res Ther. 2013;15(4):R83.","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"521_CR107","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.3899\/jrheum.131145","volume":"41","author":"H Alexanderson","year":"2014","unstructured":"Alexanderson H, Munters LA, Dastmalchi M, Loell I, Heimb\u00fcrger M, Opava CH, et al. Resistive home exercise in patients with recent-onset polymyositis and dermatomyositis\u2014a randomized controlled single-blinded study with a 2-year followup. J Rheumatol. 2014;41(6):1124\u201332.","journal-title":"J Rheumatol"},{"issue":"11","key":"521_CR108","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1093\/rheumatology\/ker292","volume":"50","author":"GE Habers","year":"2011","unstructured":"Habers GE, Takken T. Safety and efficacy of exercise training in patients with an idiopathic inflammatory myopathy\u2014a systematic review. Rheumatology (Oxford, England). 2011;50(11):2113\u201324.","journal-title":"Rheumatology (Oxford, England)"},{"issue":"5","key":"521_CR109","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1186\/s13075-014-0473-5","volume":"16","author":"MA Mattar","year":"2014","unstructured":"Mattar MA, Gualano B, Perandini LA, Shinjo SK, Lima FR, S\u00e1-Pinto AL, et al. Safety and possible effects of low-intensity resistance training associated with partial blood flow restriction in polymyositis and dermatomyositis. Arthritis Res Ther. 2014;16(5):473.","journal-title":"Arthritis Res Ther"},{"key":"521_CR110","doi-asserted-by":"crossref","unstructured":"J\u00f8rgensen AN, Aagaard P, Frandsen U, Boyle E, Diederichsen LP. Blood-flow restricted resistance training in patients with sporadic inclusion body myositis: a randomized controlled trial. Scand J Rheumatol. 2018:1\u201310.","DOI":"10.1080\/03009742.2017.1423109"},{"issue":"8","key":"521_CR111","doi-asserted-by":"publisher","first-page":"e0183292","DOI":"10.1371\/journal.pone.0183292","volume":"12","author":"JF Boehler","year":"2017","unstructured":"Boehler JF, Hogarth MW, Barberio MD, Novak JS, Ghimbovschi S, Brown KJ, et al. Effect of endurance exercise on microRNAs in myositis skeletal muscle\u2014a randomized controlled study. PLoS One. 2017;12(8):e0183292.","journal-title":"PLoS One"},{"issue":"4","key":"521_CR112","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1097\/CND.0b013e3181a23c86","volume":"10","author":"LG Johnson","year":"2009","unstructured":"Johnson LG, Collier KE, Edwards DJ, Philippe DL, Eastwood PR, Walters SE, et al. Improvement in aerobic capacity after an exercise program in sporadic inclusion body myositis. J Clin Neuromuscul Dis. 2009;10(4):178\u201384.","journal-title":"J Clin Neuromuscul Dis"}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11940-018-0521-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-018-0521-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-018-0521-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,22]],"date-time":"2019-07-22T23:29:16Z","timestamp":1563838156000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11940-018-0521-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,23]]},"references-count":112,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["521"],"URL":"https:\/\/doi.org\/10.1007\/s11940-018-0521-6","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"value":"1092-8480","type":"print"},{"value":"1534-3138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,23]]},"assertion":[{"value":"23 July 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Namita A. Goyal has received grants from Octapharma, GSK, Novartis, Idera, Orphazyme, and BMS.Tahseen Mozaffar has received grants from GSK, Novartis, Idera, Orphazyme, and BMS.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"37"}}